Global mAb Biosimilars Market 2016-2020

Global mAb Biosimilars Market 2016-2020

Category : Medical Devices
Sub Category : Biomaterials
Published On : September  2016
Pages : 103

------------ Or -------------
About Biosimilars

Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product.

Technavio’s analysts forecast the spending on the global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of 4-7% during the period 2015-2020.

Covered in this report 
The report covers the present scenario and the growth prospects of the global monoclonal antibody (mAb) biosimilars market 2016-2020. To calculate the market size, the report considers the report considers the revenue generated from the sales of mAbs. The report also considers the revenues generated from the sales of drugs that are expected to be launched during the forecast period.

The market is divided into the following segments based on geography: 
• Europe
• Asia

Technavio's report, Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
• Biocon 
• Celltrion 
• Dr. Reddy's Laboratories 
• Hospira
Other prominent vendors 
• 3SBio
• Accord Healthcare
• AET Biotech
• Allergan
• Alvartis Pharma
• Amega Biotech
• Amgen
• Apotex
• Aspen
• AstraZeneca
• Aurobindo Pharma
• Baxter
• Bharat Serums
• Bio Sidus 
• Biogen
• Bionovis
• Bioton 
• BioXpress Therapeutics
• Boehringer Ingelheim
• Boston Oncology
• Cipla
• Coherus Biosciences
• Daiichi Sankyo
• Emcure Pharmaceuticals
• Gedeon Richter
• GeneScience Pharmaceuticals 
• Hetero Drugs
• iBio 
• Intas Pharmaceuticals
• JCR Pharmaceuticals
• LG Lifesciences
• Lonza
• Merck
• Mitsubishi Tanabe Pharma
• Momenta Pharmaceuticals
• Mylan
• Natco Pharma
• Novartis
• Pfenex
• Pfizer
• Ranbaxy Laboratories 
• Roche Holding
• Samsung Biologics 
• Sanofi
• Synthon
Market driver 
•Rise in number of patent expiries 
• For a full, detailed list, view our report 

Market challenge 
• Physicians' reluctance to prescribe biosimilars
• For a full, detailed list, view our report 

Market trend 
• Emergence of biosimilars
• For a full, detailed list, view our report 

Key questions answered in this report 
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors? 

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Biosimilars: Overview
• Comparative analysis of generic small molecules and biosimilars
• Biosimilars market opportunities
• Challenges for new entrants
• Bio-betters
PART 05: Pipeline portfolio
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Market segmentation by application
• Global chronic and autoimmune diseases mAb biosimilars market
• Global oncology mAb biosimilars market
PART 08: Geographical segmentation
• Global mAb biosimilars market by geographical segmentation 2015-2020
• mAb biosimilars market in Europe
• mAb biosimilars market in Asia
• mAb biosimilars market in rest of the world
PART 09: Market drivers
• Rise in number of patent expiries
• Need for cost-effective treatment
• Reimbursement benefits for biosimilars
• Favorable government regulations
PART 10: Impact of drivers
PART 11: Market challenges
• Physicians' reluctance to prescribe biosimilars
• Multiple manufacturing complexities
• Risks related to drug failure
• Limited availability of biosimilar products
• Difficulties in patient recruitment for clinical trials
PART 12: Impact of drivers and challenges
PART 13: Market trends
• Emergence of biosimilars
• Outsourcing of manufacturing activities
• Need for high investment in R&D
• High growth in the emerging markets
• Rising number of strategic collaborations
PART 14: Vendor landscape
• Competitive scenario
PART 15: Key vendor analysis
• Biocon
• Celltrion
• Dr. Reddy's Laboratories
• Hospira
• Other prominent vendors
PART 16: Appendix
• List of abbreviations
PART 17: Explore Technavio
Enquiry Before Buy